Remove Immune Response Remove Pharmaceuticals Remove Small Molecule
article thumbnail

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Broad Institute

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

One approach is to look beyond the traditional drug molecule. Researchers are experimenting with biologics—larger biological molecules that can do things small molecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells.

article thumbnail

Rare autoantibody diseases: an innovative targeted pathway

Drug Target Review

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98
article thumbnail

Clinical Catch-Up: January 11-15 | BioSpace

The Pharma Data

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Most Read Today.

article thumbnail

A Look Back

Dark Matter Blog

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

article thumbnail

FDA Action Alert: Merck, Aurinia and Amgen

The Pharma Data

Aurinia Pharmaceutical’s Voclosporin for Lupus Nephritis. Aurinia Pharmaceuticals , based in Victoria, British Columbia and Rockville, Maryland, has a target action date of January 22 for its voclosporin. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses.

FDA 52